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Resolution of Autoimmune Oophoritis after
Thymectomy in a Myasthenia Gravis Patient
Case Report
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In tro duc ti on
Myasthenia gravis (MG) is an autoimmune disorder 
characterized by autoantibodies against acetylcholine 
receptors (1). MG is generally an isolated disorder but a 
minority of patients may develop MG in conjunction with other
autoimmune organ failures such as autoimmune thyroid 
diseases, rheumatoid arthritis, pernicious anemia and 
systemic lupus erythematosus (2,3,4,5). Premature ovarian
failure (POF) has been very rarely reported in association with
MG. We report a case with MG in whom POF has resolved
after thymectomy.
Case Report
An eighteen-year-old girl with a six-month-history of 
secondary amenorrhea was admitted to our pediatric
endocrinology clinic. Her past medical history was remarkable
for MG, presenting with ptosis and generalized muscle 
weakness developing at the end of the day. She was fifteen
years old when she was diagnosed as having autoimmune
MG. Her symptoms were partially resolved with pyridostigmine
bromide (120 mg/day) and at the eleventh month of this 
therapy, prednisolone (60 mg/day) was added. After two
months of prednisolone treatment, psychiatric symptoms
appeared which were attributed to drug-induced bipolar 
affective disorder and steroid treatment was gradually 
discontinued. The antipsychotic olanzapine (15 mg/day) was
started. Her menstrual cycles had started when she was
twelve years old and were regular until thirteen months after
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the diagnosis of MG and at the third month of olanzapine 
therapy, when menstrual irregularity had appeared. Her 
family history was unremarkable. There was no pathologic
finding in her physical examination. Her pubertal development
was evaluated as Tanner stage 5.
Since neuroleptic drugs can increase serum prolactin 
levels and cause menstrual irregularity, the patient’s prolactin
level was checked and found normal. Her gonadotropin and
inhibin B levels were in postmenapausal ranges (follicle 
stimulating hormone: 56.23 mIU/mL, luteinizing hormone  25.43
mIU/mL, inhibin B<10 pg/mL) and estrogen level was 
18 pg/mL. The patient’s hormonal levels are shown 
chronologically from the beginning of the menstrual irregularity
in Table 1. Primary ovarian insufficiency was evident with these
hormonal levels. Her suprapubic pelvic ultrasonography
revealed a large cystic formation (57x95x112 mm) in her left
ovary. For etiological investigation of autoimmune POF (APOF),
we checked antiovarian antibodies and the antibodies against
the 21-hydroxylase enzyme. They were all negative.
Acetylcholine receptor antibodies were found to be positive at
the beginning of the myasthenic symptoms. Antithyroid 
peroxidase and antityroglobulin antibodies were also negative.
We could not measure steroidogenic cell antibodies. The
patient’s myasthenic symptoms did not resolve with 
anticholinesterase therapy, and thymic enlargement was
detected by thorax magnetic resonance imaging. Since there is
a general consensus that patients with generalised MG
between puberty and 60 years of age may benefit from 
thymectomy, this surgical procedure  was performed and
pathologic examination revealed follicular thymic hyperplasia.
Three months after thymectomy, her regular menses started.
Gonadotropin levels decreased to normal ranges, but her left
ovarian cyst persisted. Six months after thymectomy, her left
ovarian cyst was removed. Pathological diagnosis was benign
mucinous cyst. Her menstrual bleeding has been regular since
thymectomy, without any hormonal replacement therapy.
Discussion
POF is characterized by amenorrhea, hypoestrogenism
and elevated serum gonadotropin levels in women younger
than 40 years (6). Among a total of 266 POF patients, 4% of
patients with spontaneous POF were diagnosed to have
autoimmune oophoritis (AO) (7). An autoimmune mechanism
was described in some patients with lymphocytic and 
plasma cell infiltration in developing follicles (8,9,10). The only
validated marker to detect AO is the presence of 
steroidogenic cell autoantibodies (7, 11). 
Coexistence of autoimmune ovarian failure and other
autoimmune diseases was reported to be between 10% and
55% (6,12,13).  APOF could be seen as a part of autoimmune
polyglandular syndrome type 1 (APGST1) (72%) and APGST2
(10%) at the age of 40 years (14). It was also reported that 
12-33% of women who presented with APOF had 
autoimmune thyroid disease as well (13,15,16,17). APOF was
also observed in patients with systemic lupus erythematosus
and MG (4,18,19,20). APOF and adrenal autoimmunity 
coexistence is the  best known but not the most frequent
association. Histological confirmation of  APOF was first
reported in a patient with autoimmune adrenal insufficiency
(8). There was lymphocytic infiltration in the secondary and
antral follicles, but primordial follicles were spared (21).
Lymphocytic infiltration was most intense in the theca layer of
the developing follicles and related with the intense 
luteinization of the follicles (7,8,9,10). Ovarian biopsy is not
recommended for the confirmation of the diagnosis in APOF.
In one study (22), highly elevated total inhibin and inhibin B
serum levels were reported in patients with APOF compared
to patients with idiopathic POF and natural menopause.
Increased inhibin B level was thought to be  a result of the 
initial preservation of granulosa cell functions. As the disease
advances, ovaries can become atrophic. In our patient, 
inhibin B level was in postmenauposal range and estrogen 
levels were low. We thought that this postmenopausal inhibin
B level was the result of an advanced stage of the ovarian
destruction in our patient. We did not perform ovarian biopsy
at the time of diagnosis. However, six months after 
thymectomy, a benign mucinous ovarian cyst was removed.
The pathology of the cyst showed no lymphocytic and 
plasma cell infiltration. At the time of the ovarian operation,
our patient had been having regular menstrual bleeding and
normal gonadotropin and sex steroid levels for six months.
Tab le  1.  Laboratory evaluation of the patient in a chronological order
Dec 12,2007 Jan 8, 2009 May 4, 2009 Oct 7, 2009
FSH  (mIU/mL) 5.6 56.2 51.3 9.6
LH  (mIU/mL) 4.0 25.4 32.2 6.1
E2 (pg/mL) 10.0 18.0 <10 68.0
Prolactin  (ng/mL) (5.18-26 ng/mLl) 13.5 12.0
Inhibin B (pg/mL)  <10
21-hydroxylase autoantibody  (<0.5 U/ml) 1.0
FSH: follicle-stimulating hormone, LH: luteinizing hormone, E2: estradiol214
We thought that this was the reason we could not find 
lymphocytic and plasma cell infiltration representing AO.
However, it has been recently reported that lymphocytic and
plasma cell infiltration may be absent and selective 
mononuclear cell infiltration free of lymphocytes may be
observed in AO (23). Antibodies against steroid cell antigens
obtained from adrenal tissue substrates are the most 
validated marker for the diagnosis of APOF that correlates
with ovarian inflammation (7). We could only study anti-21-
hydroxylase and antiovarian antibodies and they were 
negative. The predictive value of the commercially available
antiovarian antibody test is poor. One study (24) showed that
these tests use animal ovarian tissues and have an 
unacceptably high false-positive rate.
Large ovarian cysts have been reported in several patients
with AOF. As a result of follicular dysfunction, impaired 
negative feedback lead to elevated gonadotropin levels which
overstimulate the ovarian tissues and lead to the development
of large luteinized ovarian cysts (25,26,27,28,29). Initially, we
thought that our patient’s large ovarian cyst had developed
with this mechanism. However, we did not observe any
regression in this large ovarian cyst after thymectomy
although her regular menstruation resumed.  On the other
hand, thymectomy has been reported to induce autoimmune
ovarian dysgenesis and autoimmune dacryoadenitis in mice.
However, the significance of this finding in humans especially
in the setting of MG is not clear (30).
Coexistence with another autoimmune disease is not a
criterion for the diagnosis of APOF. However, our patient had
primary ovarian failure and her ovarian insufficiency resolved
after thymectomy. For this reason, we thought she had AO. 
There is no controlled research about the treatment of
AOF, but steroid therapy 20-40 mg/day and cyclic 
estrogen-progesterone replacement therapy have been
reported to be successful in several case reports and case
series in adults (31). We did not use steroid therapy, because
our patient had developed steroid-related bipolar affective
disorder during the therapy for MG.
In 1969, Lundberg and Person   reported a 25-year-old
MG female patient with POF and her menstrual cycles
became regular eight weeks after thymectomy (5). The
authors thought that her ovarian failure had an autoimmune
etiology.  In 1993, a 27-year-old patient with POF and MG was
reported to have had thymectomy one year after the initial
diagnosis during which she received   pyridostigmine and 
hormone replacement therapy. Spontaneous pregnancy
occurred three years after thymectomy (32). 
Our patient was not on hormonal replacement before and
after thymectomy. Her regular menses started three months
after thymectomy. To our knowledge, this is the first report on
a patient with autoimmune ovarian insufficiency and MG in
whom premature ovarian insufficiency resolved after 
thymectomy without hormonal therapy. We therefore suggest
that treatment of MG including thymectomy if indicated may
lead to resolution of the ovarian failure and hormonal therapy
may not be necessary. If hormonal therapy had been 
introduced before MG was successfully treated; a trial of 
discontuniation of cyclic hormone replacement may reveal
ovarian recovery.
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